Atria Investments Inc Purchases 14,424 Shares of Genmab A/S (NASDAQ:GMAB)

Atria Investments Inc grew its position in shares of Genmab A/S (NASDAQ:GMAB) by 42.4% in the third quarter, Holdings Channel reports. The fund owned 48,475 shares of the company’s stock after buying an additional 14,424 shares during the quarter. Atria Investments Inc’s holdings in Genmab A/S were worth $1,182,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of GMAB. Russell Investments Group Ltd. boosted its position in shares of Genmab A/S by 137.7% during the 1st quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after acquiring an additional 544 shares during the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Genmab A/S during the 1st quarter valued at approximately $43,000. Blue Trust Inc. boosted its position in shares of Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after acquiring an additional 3,880 shares during the last quarter. Headlands Technologies LLC boosted its position in shares of Genmab A/S by 1,702.8% during the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares during the last quarter. Finally, Benjamin F. Edwards & Company Inc. boosted its position in shares of Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after acquiring an additional 478 shares during the last quarter. 7.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on GMAB shares. JPMorgan Chase & Co. restated a “neutral” rating on shares of Genmab A/S in a research report on Tuesday, August 20th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Genmab A/S in a research report on Wednesday, October 16th. Morgan Stanley restated an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research report on Wednesday, September 11th. Truist Financial lowered their price target on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Genmab A/S presently has a consensus rating of “Moderate Buy” and an average target price of $45.20.

Genmab A/S Stock Down 2.8 %

GMAB stock opened at $20.59 on Friday. The business’s fifty day simple moving average is $23.81 and its two-hundred day simple moving average is $26.18. Genmab A/S has a twelve month low of $20.50 and a twelve month high of $32.89. The firm has a market cap of $13.63 billion, a price-to-earnings ratio of 19.99, a PEG ratio of 0.68 and a beta of 0.99.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The business had revenue of $816.10 million during the quarter, compared to analysts’ expectations of $838.20 million. During the same quarter in the previous year, the business earned $0.47 EPS. Research analysts expect that Genmab A/S will post 1.28 EPS for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.